1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Indaptus Therapeutics agreed on September 8, 2026 to sell 20,338,974 shares of common stock to purchasers in a private placement for aggregate gross proceeds of about $24.0 million before offering expenses. The company plans to use the proceeds for working capital, research and development, and general corporate purposes, possibly including early-stage work on a neurotechnology device for sleep-related conditions. The shares are unregistered, and the company must later file a resale registration statement, which could add shares to the market.
Shares sold: 20,338,974 shares of common stock at a price equal to the Nasdaq Minimum Price plus $0.015 per share
Gross proceeds: approximately $24.0 million before offering expenses
Closing: subject to customary conditions, no later than the fifteenth business day after September 8, 2026
Shares were sold under Section 4(a)(2) and/or Regulation S and are subject to transfer restrictions
Group 1 Automotive agreed to sell $1.25 billion of senior unsecured notes in two tranches, due 2032 and 2035, with expected net proceeds of about $1,236.0 million and closing expected on September 22, 2026. The company plans to use the proceeds, with cash on hand, to fund its pending purchase of dealership assets and related real estate from Hennessy Automobile Companies, and the filing says the 2032 notes must be redeemed if that acquisition is not completed by the outside date.
$625.0 million of 6.250% senior notes due 2032 and $625.0 million of 6.625% senior notes due 2035, sold at par
Expected net proceeds of approximately $1,236.0 million; closing expected September 22, 2026
If the Hennessy Acquisition is not consummated by January 6, 2027, or any extended date, the 2032 notes must be redeemed at 100% of issue price plus accrued interest
Affiliates of certain initial purchasers are lenders under the company's revolving credit facility and will receive a portion of the net proceeds
PAVmed Inc. signed a Sales Agreement with A.G.P./Alliance Global Partners that lets it sell common stock through the agent from time to time, up to $9,400,000 of shares under its current prospectus supplement. The company says it plans to use net proceeds for working capital and general corporate purposes, and the sales would dilute existing shareholders.
Maximum offering under the current prospectus supplement is $9,400,000 of common stock.
The agent's commission is 3.0% of aggregate gross sales prices, plus legal cost reimbursements of up to $65,000 at signing.
Shares are offered under a Form S-3 shelf registration declared effective April 15, 2025, with a prospectus supplement dated September 9, 2026.
Either party may terminate the agreement on ten business days' written notice.
HCW Biologics filed an amended preliminary proxy statement on September 9, 2026, after the board decided not to seek stockholder approval of Proposal No. 2, an amended performance-based equity plan for eligible officers, directors and employees. The amendment also changes the Special Meeting date, the record date and certain other dates.
Proposal No. 2, an amended performance-based equity plan, was removed from the proxy after stockholder feedback.
The amendment changes the date of the Special Meeting of Stockholders and the record date.
The original preliminary proxy statement was filed with the SEC on September 8, 2026.
No other substantive changes were made to the original preliminary proxy statement, per the filing.
Plains All American Pipeline priced $700 million of 6.75% Series A and $800 million of 7.00% Series B junior subordinated notes due 2056, expected to close September 14, 2026. The company plans to use the proceeds, with cash on hand and commercial paper, to redeem all of its outstanding Series A and Series B preferred units. The filing replaces preferred units with junior debt but does not state the effect on earnings or distributions.
$700 million of 6.75% Series A and $800 million of 7.00% Series B junior subordinated notes due 2056 priced, with closing expected September 14, 2026
Proceeds, cash on hand and commercial paper to redeem all 58,411,908 Series A preferred units and all 800,000 Series B preferred units
Series A units redeemed at $28.875 per unit (110% of $26.25 par) on or about September 14, 2026; Series B at $1,000 par on or about October 9, 2026
STAAR Surgical appointed David Bailey, its former President and Chief Executive Officer, as Chief Commercial Officer effective September 8, 2026. He reports to CEO Warren Foust, and the filing sets out his base salary, bonus target and equity awards, which shareholders can review in the offer letter filed as Exhibit 10.1.
Appointed Chief Commercial Officer effective September 8, 2026; reports to Warren Foust, President and CEO
Base salary at an annual rate of CHF 462,825 (approximately $575,000), with a 2026 target bonus of 60% of base salary, prorated
Initial RSU grant valued at $850,000 vesting over three years, plus a 2026 long-term incentive award valued at $1,400,000, prorated
Mr. Bailey previously served as STAAR's President and CEO from 2001 to 2008 and as President, International Operations, from 2008 to 2011
Principal Financial Group and two subsidiaries entered into an amended and restated five-year credit facility with Wells Fargo as administrative agent, refinancing the company's existing revolving facility dated October 18, 2022. The facility allows borrowing of up to $900 million, with a commitment termination date of September 9, 2031, and no borrowings are currently outstanding; this is a routine financing update with no new debt drawn.
Facility allows borrowing of up to $900 million, expandable to a maximum of $1.3 billion subject to conditions
Commitment termination date of September 9, 2031, with up to two 1-year extensions
No borrowings outstanding under the facility as of filing
Financial covenants include minimum Statutory Surplus of $2,885,208,297 and Total Debt to Total Capital ratio not exceeding 35%
Enbridge agreed with an underwriting syndicate led by RBC Capital Markets and CIBC Capital Markets to sell 38.9 million common shares at CDN$66.85 each, for gross proceeds of CDN$2.6 billion. The company plans to use the net proceeds to partially fund announced acquisitions and to create financial flexibility for future growth, which would add new shares outstanding for existing holders.
Offering of 38,900,000 common shares at CDN$66.85 per share, for aggregate gross proceeds of CDN$2.6 billion
Offering expected to close on or about September 14, 2026
Underwriters hold an option for up to 15% more shares, which would bring gross proceeds to about CDN$3.0 billion if fully exercised
Net proceeds intended to partially fund announced acquisitions and provide financial flexibility
Build-A-Bear Workshop's board declared a quarterly cash dividend of $0.23 per share on September 9, 2026, payable October 8, 2026 to holders of record at the close of business on September 24, 2026. The filing is a routine dividend announcement and does not report new financial results or change guidance. The accompanying press release notes fiscal 2025 total revenues of $529.8 million, the company's fifth consecutive year of record results.
Quarterly cash dividend of $0.23 per share declared September 9, 2026
Record date is September 24, 2026, at the close of business
Dividend payment date is October 8, 2026
Press release (Exhibit 99.1) cites fiscal 2025 total revenues of $529.8 million
Wrap Technologies amended the employment agreements of Chief Executive Officer Scot Cohen and President and Chief Operating Officer Jared Novick and approved performance restricted stock grants to each on September 2, 2026. The awards total 6,000,000 shares and vest only if the company's market capitalization meets thresholds from $150.0 million to $506.25 million, with part of the shares also tied to a stockholder vote to increase the equity plan's authorized shares. The filing also extends the post-termination exercise period on certain prior stock options from three months to 24 months.
Scot Cohen receives 4,000,000 performance restricted stock shares; Jared Novick receives 2,000,000, approved September 2, 2026.
Shares vest in tranches when market capitalization meets $150.0 million, $225.0 million, $337.5 million and $506.25 million for 45 consecutive trading days.
1,600,000 Cohen shares and 800,000 Novick shares are void if stockholders do not approve an equity plan increase by March 15, 2027.
Both employment agreements set a $200,000 annualized base salary and a two-year initial term, with 12-month automatic renewals.
Investar Holding Corp CEO John J. D'Angelo adopted a Rule 10b5-1 trading plan on September 4, 2026, to exercise stock options expiring in March 2027 and sell the resulting shares. The plan takes effect December 3, 2026, and expires on or before March 31, 2027, with trades reported on Form 4 filings.
Plan covers up to 16,952 stock options expiring in March 2027
Plan adopted September 4, 2026; effective December 3, 2026; expires on or before March 31, 2027
Company says D'Angelo continues to hold a significant number of fully-vested shares above ownership guidelines
KALA BIO's board set November 3, 2026 as the date of its next annual stockholders meeting. Stockholders who want to submit proposals for inclusion in the proxy materials, or nominate directors, must do so by September 19, 2026, because the meeting date moved by more than 30 days from the prior anniversary.
Annual meeting date set for November 3, 2026; the board set the date on September 9, 2026
Deadline for Rule 14a-8 stockholder proposals for proxy inclusion: September 19, 2026
Deadline for director nominations and other proposals under the By-Laws: September 19, 2026, at the company's Arlington, Massachusetts offices
Meeting time, location and voting matters will be detailed in the proxy statement
Community Trust Bancorp said it will present to investors on September 10, 2026, at the Raymond James U.S. Bank and Banking on Technology Conferences in Chicago. The slides cover current and historical financial results and future performance goals, and are furnished as Exhibit 99.1. The filing contains no new financial figures in the text provided, so it is a routine investor-relations disclosure.
Presentation scheduled for Thursday, September 10, 2026, in Chicago, Illinois
Slides cover current and historical financial results and future performance goals
Investor presentation furnished as Exhibit 99.1 and not deemed filed under Section 18 of the Securities Exchange Act of 1934
Filing signed September 9, 2026 by Chairman, President and CEO Mark A. Gooch
Candel Therapeutics furnished a September 2026 corporate presentation under Regulation FD, for use with investors and analysts. The deck restates Phase 3 results for aglatimagene in localized, intermediate- to high-risk prostate cancer, including extended follow-up data presented at AUA 2026, and reports cash and cash equivalents of $201.6 million as of June 30, 2026. The filing contains no new financial results or guidance.
Phase 3 trial (n=745) met its primary endpoint of disease-free survival, with a hazard ratio of 0.70 (95% CI 0.52 to 0.94; P=0.0155) in the intent-to-treat population.
Extended follow-up data (data cutoff March 15, 2026) showed prostate cancer-specific DFS hazard ratio of 0.61 (95% CI 0.44 to 0.85; P=0.0031).
Cash and cash equivalents were $201.6 million as of June 30, 2026, with expected runway into Q1 2028.
Financing includes a term loan facility with Trinity Capital of up to $130 million (October 2025) and a $100 million royalty funding agreement with RTW Investments (February 2026), subject to approval of aglatimagene in localized prostate c
Diversified Energy Company agreed on September 2, 2026 to acquire Birch Permian Holdings and related companies in a transaction with an aggregate purchase price of approximately $1.8 billion, including repayment of indebtedness. The deal adds about 46,000 net mineral acres in the Midland Basin plus midstream and water infrastructure, and is expected to close in the fourth quarter of 2026 subject to customary conditions. The company expects to fund roughly $1.5 billion through an asset-backed securitization, with the remainder from other sources including its revolving credit facility.
Aggregate purchase price of approximately $1.8 billion, subject to adjustments
Expected funding includes an asset-backed securitization of approximately $1.5 billion before closing
Merger Agreement requires a $50 million deposit; a $50 million termination fee applies in certain cases
Expected closing in the fourth quarter of 2026, subject to customary closing conditions
AT&T's Board increased its size from 10 to 11 members, effective September 8, 2026, and elected Fazal F. Merchant to fill the new seat. The Board determined Merchant is independent under New York Stock Exchange standards and appointed him to the Audit and Corporate Development and Finance Committees. The filing is administrative and does not report financial results or a change in leadership of the company.
Board size increased from 10 to 11 members, effective September 8, 2026
Fazal F. Merchant elected Director to fill the resulting vacancy
Merchant appointed to the Audit and Corporate Development and Finance Committees
Board determined Merchant is independent under NYSE standards
Alico's board declared a fourth quarter fiscal 2026 cash dividend of $0.05 per share on September 8, 2026. Shareholders of record as of October 2, 2026 will receive payment on or around October 16, 2026, per the filing's stated expectation.
Dividend amount: $0.05 per share on outstanding common stock
On September 9, 2026, CenterPoint Energy and its subsidiaries Houston Electric, CERC and SIGECO replaced their existing revolving credit facilities with four new five-year facilities totaling $4.6 billion in aggregate commitments. The company reported that no termination penalties were incurred on the earlier facilities. The filing describes a refinancing of existing credit capacity rather than a change in the company's earnings or guidance.
CenterPoint Energy parent replaced its $2.4 billion facility, dated December 6, 2022, with a new $2.2 billion facility, with a request option for increases up to $2.5 billion.
Houston Electric replaced a $300 million facility with a new $1.0 billion facility; CERC replaced $1.05 billion with $1.1 billion; SIGECO replaced $250 million with $300 million.
The parent facility limits debt to consolidated capitalization to 67.5%, temporarily raised to 70% after certain natural disaster certifications.
JPMorgan Chase Bank, N.A. serves as administrative agent for the parent facility and will serve as agent for the other three facilities.
Rallybio's Chief Financial Officer, Jonathan Lieber, will move to part-time employment effective September 15, 2026, but will remain CFO and Principal Financial Officer with the same duties and authority. His employment will end when the pending business combination with Avenzo Therapeutics closes, unless it is terminated earlier.
Part-time transition effective September 15, 2026; he keeps the CFO and principal financial officer titles
Base salary of $420,000 after the transition, with benefit plan participation
No annual bonus for 2026 or any later year he is employed
Employment ends at the closing of the Avenzo merger agreement dated May 31, 2026; severance follows under his existing employment agreements
BJ's Restaurants, Inc. appointed Christopher W. Brandt and James D. White as independent directors, effective September 3, 2026. The Board's authorized seats rose from eight to ten under the company's bylaws, and the filing describes the new directors' backgrounds in restaurant marketing and public company leadership.
Effective September 3, 2026, Brandt and White joined the Board; Brandt serves on the Governance and Nominating Committee and White on the Compensation Committee.
Authorized directors increased from eight to ten under Article III, Section 2 of the Bylaws.
Brandt was President, Chief Brand Officer and Chief Marketing Officer at Chipotle Mexican Grill from 2018 to 2026.
White was Chair, President and Chief Executive Officer of Jamba Juice from 2008 to 2016.
Amazon's board elected cybersecurity executive Kevin R. Mandia as a director on September 8, 2026, and appointed him to the Audit Committee and Security Committee. He receives a restricted stock unit award for 4,086 shares that vests in three equal annual installments starting November 15, 2027, if he continues to serve. The change adds a director with cybersecurity leadership experience to oversight of audit and security matters.
Elected as director on September 8, 2026, and appointed to the Audit Committee and Security Committee
Restricted stock unit award for 4,086 shares, vesting in three equal annual installments beginning November 15, 2027
Mr. Mandia previously served as CEO of Mandiant, Inc. from June 2016 to July 2024 and is CEO of Armadin, Inc.
Filing also discloses that an employee, Kristin Mandia, is his sister-in-law, with an annual salary of $185,000
Hagerty, Inc. announced that its majority holder, Hagerty Holding Corp., plans an underwritten secondary offering of 8,250,000 shares of Hagerty Class A common stock, with a 30-day option for underwriters to buy up to 1,237,500 more. Hagerty will not receive any proceeds from the sale, so the offering does not raise capital for the company, though Hagerty will bear its own expenses of the offering.
Selling stockholder Hagerty Holding Corp. intends to offer 8,250,000 Class A shares.
Underwriters have a 30-day option to purchase up to 1,237,500 additional shares.
Hagerty receives no proceeds; Hagerty Holding Corp. bears its underwriting discount and the company bears remaining expenses.
Wells Fargo Securities and J.P. Morgan are lead bookrunning managers, per the September 9, 2026 press release.
Selling stockholders affiliated with TDR Capital agreed to sell 14,000,000 Target Hospitality common shares at $18.50 per share in an underwritten offering, and the company will not receive any of the proceeds. Separately, the company agreed to buy back shares from the underwriters for approximately $30 million, funded with cash on hand and ABL Credit Facility borrowings, with the closing expected on September 10, 2026.
14,000,000 shares offered by Arrow Holdings S.à r.l. and MFA Global S.à r.l. at $18.50 per share, for approximately $259,000,000 in gross proceeds to the selling stockholders
Company will not receive any proceeds from the offering
Company to repurchase shares from the underwriters for approximately $30,000,000, to be held as treasury shares and funded with cash on hand and ABL Credit Facility borrowings
Underwriters have a 30-day option to buy up to 2,100,000 additional shares; closing is expected on September 10, 2026
Enbridge said a wholly-owned subsidiary has signed a definitive agreement to acquire Tallgrass Energy's crude oil transportation, gathering, storage and terminaling business for U.S.$2.55 billion in cash, subject to customary closing adjustments. Enbridge expects the deal to be accretive to distributable cash flow per share in the first full year of ownership, and says its 2026 financial guidance is not materially affected because closing is expected later in 2026.
Cash consideration of U.S.$2.55 billion, representing an estimated acquisition multiple of 10-11x forward enterprise value to EBITDA.
Assets include 75% of Pony Express Pipeline, 51% of Powder River Gateway system, and about 8.4 million barrels of storage across nine crude terminals.
PXP2 expansion of U.S.$0.3 billion is expected to increase Pony Express capacity to about 515 kbpd, with service expected in late 2027.
Closing is expected later in 2026, subject to regulatory approvals including Federal Trade Commission clearance; an equity offering will partially fund the deal.
Director Frederick J. Elmy retired from the RBC Bearings board on September 3, 2026, the same day as the annual stockholder meeting. Stockholders elected the company's director nominees, ratified Ernst & Young LLP as auditor for fiscal 2027, and approved executive pay on an advisory basis, so these are routine governance outcomes.
Frederick J. Elmy retired from the Board of Directors on September 3, 2026.
Dr. Michael J. Hartnett received 27,410,015 for votes and Dolores J. Ennico received 21,681,115 for votes in the Class III director election.
Ernst & Young LLP was ratified as independent auditor for fiscal year 2027 with 29,148,374 for votes against 310,987.
Advisory say-on-pay proposal received 26,967,486 for votes against 1,172,452.
Essential Properties Realty Trust promoted Chief Operating Officer R. Max Jenkins to President and Chief Operating Officer, expanded Robert W. Salisbury's role to include Chief Strategy Officer, and named Craig Vachris Chief Investment Officer after A Joseph Peil's employment ended September 8, 2026. CEO Peter M. Mavoides continues in his role and signed a new employment agreement, which matters to shareholders because it reshapes the senior team that runs investments and strategy.
Jenkins appointed President and Chief Operating Officer; Mavoides remains Chief Executive Officer, with amended employment agreements effective September 8, 2026 running through March 31, 2031
Jenkins and Salisbury received promotion grants of long-term incentive plan units with a target grant date value of $2,000,000, vesting 50% at three and four years
Craig Vachris, with more than 20 years of commercial real estate and net lease experience, named Executive Vice President and Chief Investment Officer
Peil's employment ended September 8, 2026, and he is eligible for severance for a termination without cause
Fortune Brands Innovations appointed Peter G. Clifford as Executive Vice President and Chief Financial Officer, effective September 21, 2026. Interim CFO Ashley George will return to her prior role as Senior Vice President, Finance. The filing also sets out Clifford's pay and inducement equity awards, which are granted outside the company's 2022 Long-Term Incentive Plan.
Clifford, 56, was CFO of Filtration Group Corporation until August 2026.
Base salary of $700,000, annual bonus target of 90% of base salary, and long-term incentive target of $1,950,000.
Inducement awards: performance-based RSUs on 130,000 shares and stock options on 65,000 shares, to be granted September 28, 2026.
Ashley George, Interim CFO, will become Senior Vice President, Finance.
Luxfer Holdings said the U.S. Hart-Scott-Rodino waiting period for its proposed acquisition by Double Eagle Acquisition Buyer, Inc., a holding company owned by funds managed by Wynnchurch Capital, expired at 11:59 p.m. EDT on September 8, 2026. That clears one of the closing conditions, but the deal still requires shareholder approval, certain other regulatory approvals and High Court sanction in England and Wales.
HSR waiting period expired at 11:59 p.m. EDT on September 8, 2026.
The transaction is a scheme of arrangement under Part 26 of the U.K. Companies Act 2006, under a Transaction Agreement dated July 26, 2026.
Remaining conditions include shareholder approval and certain other regulatory approvals.
A preliminary proxy statement was filed with the SEC on August 26, 2026.
Century Therapeutics added Joseph Truitt, chief executive of iECURE, Inc., as a director effective September 9, 2026, increasing the board from six to seven members. Truitt will also serve on the Compensation Committee and receive standard non-employee director pay, including a stock option award and an annual cash retainer, so the appointment adds a board member with biotechnology executive experience.
Truitt appointed effective September 9, 2026 as a Class I director with a term expiring at the 2028 Annual Meeting of Stockholders
Board size increased from six to seven directors; Truitt will serve on the Compensation Committee
Initial option grant of 148,000 shares of common stock, vesting in equal monthly installments over 36 months, plus an annual cash retainer of $40,000
Board determined Truitt is independent under Nasdaq listing rules
At an extraordinary general meeting on September 8, 2026, shareholders approved extending Andretti Acquisition Corp. II's deadline to complete a business combination from September 9, 2026 to September 9, 2027, or an earlier date set by the board. Holders of 15,776,190 Public Shares redeemed them for cash, an aggregate of approximately $171.69 million, leaving 7,223,810 Public Shares outstanding.
Extension Amendment vote: 23,241,840 for, 2,775,781 against, 0 abstentions
Meeting Redemptions: 15,776,190 Public Shares at approximately $10.88 per share, about $171.69 million in total
On September 8, 2026, the Company and Sponsor signed a new non-redemption agreement covering up to 650,000 Non-Redeemed Shares
Sponsor converted 5,749,999 Class B shares into Class A; after the conversion and redemptions there are 13,733,809 Class A and one Class B ordinary share outstanding
Joby Aviation's Board appointed Sergey Novikov, the company's Controller since June 2021, as Principal Accounting Officer on September 2, 2026, effective immediately. The filing states his pay and other arrangements continue unchanged from before the promotion, so the change is administrative and does not alter compensation terms disclosed in the filing.
Board appointed Sergey Novikov as Principal Accounting Officer on September 2, 2026, effective immediately
Novikov has been Controller since June 2021 and was acting principal accounting officer from December 13, 2024 through May 29, 2025
Compensatory arrangements continue as in effect before the promotion; he will sign the company's standard indemnification agreement
Filing states no arrangements or understandings tied to the appointment and no related-party transactions under Item 404(a)
FitLife Brands, Inc. began using a new corporate presentation for business purposes on September 9, 2026, and furnished a copy as Exhibit 99.1 to its Form 8-K. The filing contains no financial results, guidance, or transaction terms, and the company states the information is furnished under Regulation FD and not deemed filed under the Exchange Act.
Presentation dated September 2026 began use on September 9, 2026
Full copy filed as Exhibit 99.1 with the Form 8-K
Filing states no financial results, guidance, or transaction terms in the body text
AEye's Compensation Committee approved a one-time award of 100,000 restricted stock units to Chief Financial Officer Conor Tierney on September 2, 2026, recognizing his work on the Lunar Outpost engagement and the commercial pipeline. The units vest in full on November 15, 2026, if he remains with the company, and each unit settles in one common share, so the award adds potential dilution for shareholders.
Award: 100,000 restricted stock units to CFO Conor Tierney, approved September 2, 2026
Vesting: full vesting on November 15, 2026, subject to continued service
Settlement: each unit that vests converts into one share of AEye common stock
Horizon Funding II, a wholly owned subsidiary of Horizon Technology Finance Corporation (HRZN), signed amendments on September 2, 2026 to its securitization financing documents, including a second supplemental indenture and a second amended and restated note funding agreement. The filing says the amendments extend the Legal Final Payment Date to December 10, 2035, but it does not disclose the size of the notes or any change in interest cost, so the financial effect for shareholders is not quantified.
Amendments dated September 2, 2026 cover the indenture, note funding agreement and sale and servicing agreement for Horizon Funding II, LLC.
The Legal Final Payment Date is extended to December 10, 2035.
The filing references the original indenture dated June 21, 2024 and prior amendments dated May 23, 2025.
The 8-K was signed by CEO Michael P. Balkin on September 9, 2026.
National Rural Utilities Cooperative Finance Corporation (CFC) said it will redeem all $400 million of its 5.60% Medium-Term Notes due 2026 on October 13, 2026, at par plus accrued interest. The company said the redemption is intended to reduce interest expense and will be paid with cash on hand.
Redemption of all $400 million of 5.60% Medium-Term Notes due 2026 (CUSIP 63743HFK3) on October 13, 2026
Notes redeemed at par plus accrued interest
Stated purpose is to reduce interest expense; funded with cash on hand
Notice to investors was provided on September 8, 2026
Procore Technologies said it completed its merger with DroneDeploy on September 9, 2026, under a merger agreement first announced July 27, 2026. Procore acquired DroneDeploy for an approximate purchase price of $845.0 million in cash, subject to adjustments for working capital, transaction expenses, cash and indebtedness. The filing gives no financial results for either company, so its effect on Procore's earnings is not stated.
Merger completed September 9, 2026; DroneDeploy is now a wholly-owned subsidiary of Procore
Approximate purchase price of $845.0 million in cash, subject to adjustments
Merger agreement originally entered into July 27, 2026, and reported in an 8-K filed July 29, 2026
Castellum, Inc. said its CEO Glen Ives and CFO David Bell will present at the H.C. Wainwright Global Investment Conference on September 15, 2026, in New York, and will hold one-on-one investor meetings. The filing contains no financial results, guidance, or new business terms, so it gives shareholders no new information about the company's performance.
Presentation date: Tuesday, September 15, 2026, at the Lotte New York Palace Hotel
Presenters: CEO Glen Ives and CFO David Bell
Webcast available on H.C. Wainwright's conference website beginning Friday, September 11 at 7:00 a.m. E.T.
The filing includes no financial results or guidance
Lee Enterprises' Audit Committee approved dismissing BDO USA, P.C. as its independent auditor on September 2, 2026, after a competitive evaluation tied to a potential audit firm rotation. Grant Thornton LLP was approved as the replacement for the fiscal year ending September 26, 2027, and the change takes effect after BDO completes its fiscal 2026 audit and the company files its annual report.
Audit Committee approved BDO's dismissal on September 2, 2026; the change takes effect after BDO's fiscal 2026 audit and Form 10-K filing.
Grant Thornton LLP approved as auditor for the fiscal year ending September 26, 2027, subject to customary client acceptance procedures.
BDO's reports for fiscal 2025 and 2024 contained no adverse or disclaimer of opinion and were not qualified or modified.
A material weakness in internal controls over certain revenue transactions existed through June 23, 2024 and was remediated as of September 29, 2024.
Educational Development Corporation announced that its second quarter fiscal year 2027 earnings call will be held on Wednesday, October 14, 2026, at 3:30 PM CT (4:30 PM ET). The filing contains no financial results, so the announcement is administrative and does not change the company's reported performance.
Earnings call scheduled for Wednesday, October 14, 2026, at 3:30 PM CT (4:30 PM ET)
Craig White, Heather Cobb and Dan O'Keefe are scheduled to present the second quarter results
Live Q&A webcast; audio replay to be posted at www.edcpub.com/investors
SRX Global entered a Limited Consent and Amendment Agreement on September 8, 2026, under which holders of its Series C convertible preferred stock consented to and waived certain rights so the company can maintain a stock repurchase plan. The plan allows repurchases of up to the lesser of 10,000,000 shares or 50% of outstanding common stock, for an aggregate price not to exceed $20,000,000, through July 7, 2027. The filing does not state how much stock the company has bought back or plans to buy back.
Consent Agreement dated September 8, 2026, between the company and the Required Holders of Series C preferred stock
Repurchase plan cap: lesser of 10,000,000 common shares or 50% of outstanding common stock, up to $20,000,000 in aggregate purchase price
Plan period ends July 7, 2027
Related August 27, 2026 sale of 3,579 Series C preferred shares for $2.825 million; the Series C shares are convertible into common stock
CME Group announced senior leadership changes in its finance and legal divisions. Jack Tobin becomes Deputy Chief Financial Officer on November 2, 2026, and Chief Financial Officer in March 2027, when Lynne Fitzpatrick becomes Chief Executive Officer. The changes also bring a new General Counsel, John Marchese, and a new Chief Accounting Officer, Matthew Render, but the filing gives no financial results or figures tied to these appointments.
Jack Tobin becomes Deputy Chief Financial Officer on November 2, 2026, and Chief Financial Officer in March 2027, when Lynne Fitzpatrick becomes Chief Executive Officer.
Matthew Render succeeds Tobin as Managing Director, Chief Accounting Officer effective November 2, 2026, after joining CME Group in August 2026.
John Marchese is promoted to General Counsel, succeeding Jonathan Marcus, who has served as General Counsel since 2022 and is stepping down later this month.
Tobin previously planned to retire effective October 30, 2026, but will now continue with the company.
The New York Times Company said Executive Vice President and Chief Human Resources Officer Jacqueline Welch will step down effective January 1, 2027. The filing says she will be eligible for severance under the company's Executive Severance Plan, subject to a general release and restrictive covenants, and is entitled to payments under long-term performance awards because she meets the retirement requirements.
Jacqueline Welch steps down as Executive Vice President and Chief Human Resources Officer, effective January 1, 2027
Severance eligibility under the Executive Severance Plan is subject to a general release of claims and compliance with restrictive covenants
Welch has met the age and service requirements for Retirement under awards granted under the 2020 Incentive Compensation Plan and is entitled to payments under those awards
Limbach Holdings and subsidiaries entered a five-year, $300.0 million credit agreement with PNC Bank, National Association, maturing September 9, 2031. The new facility replaces the company's existing $125.0 million Wintrust revolving credit facility, which was terminated after about $118.1 million of principal was repaid from PNC proceeds, with no early termination penalties reported.
Facility totals up to $300.0 million: $200.0 million revolver, $50.0 million term loan and $50.0 million delayed draw term loan
Loans priced at Base Rate plus 0.50% to 1.50%, or Term SOFR plus 1.50% to 2.50%, based on net leverage
Financial covenants require maximum net leverage of 3.00 to 1.00 and minimum fixed charge coverage of 1.15 to 1.00
About $7.0 million of existing letters of credit remain outstanding under the former Wintrust agreement until they expire, with latest expiry in April 2027
Immunic, Inc. is hosting a Relapsing Multiple Sclerosis (RMS) Research and Development Day webinar on September 9, 2026, from 11:00 a.m. to 12:30 p.m. ET, and has filed a presentation for the event as Exhibit 99.1. The filing contains no financial results, guidance, or new clinical data beyond the presentation itself, so the event is routine for shareholders.
RMS R&D Day webinar held September 9, 2026, 11:00 a.m. to 12:30 p.m. ET by video conference
Company presentation dated September 9, 2026 furnished as Exhibit 99.1
Filing is furnished under Regulation FD and not deemed filed under Section 18 of the Exchange Act
Daré Bioscience filed a Form 8-K furnishing a corporate presentation dated September 9, 2026, as Exhibit 99.1, for use in meetings with securities market participants starting that day. The filing is administrative and contains no financial results, guidance, or deal terms in the text provided, and the presentation content was not included in the filing text.
Corporate presentation dated September 9, 2026 furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure)
Company plans to use the presentation in investor meetings commencing September 9, 2026
Presentation to be posted on the Investors section of the company website, ir.darebioscience.com
Intelligent Bio Solutions said it submitted a 510(k) premarket notification to the FDA seeking clearance of its Intelligent Fingerprinting Drug Screening System for detecting codeine. The company says the submission is based on a 2026 clinical program and that FDA clearance is expected to expand its addressable U.S. market beyond forensic-use-only settings. The filing does not state a clearance timeline or any financial figures.
Submission announced September 9, 2026 for codeine detection on the Intelligent Fingerprinting Drug Screening System
Method Comparison Study reported accuracy above 98%, sensitivity above 94% and 100% specificity across three U.S. clinical sites
Cybersecurity review reported 100% of medium-risk vulnerabilities remediated and all 19 SBOM vulnerabilities resolved
Filing gives no FDA review timeline and no financial results or guidance
Genuine Parts Company said board member Court Carruthers has been appointed Chief Executive Officer-Elect, effective September 8, 2026, and will become CEO when the planned separation of its Automotive and Industrial businesses closes. The separation is targeted for the first quarter of 2027, and Will Stengel will remain Chairman and CEO until then before joining Motion as its Chairman and CEO. The changes set the leadership structure for the two standalone companies that shareholders will hold after the separation.
Court Carruthers: CEO-elect effective September 8, 2026, with a base salary of $1,000,000 that rises to $1,200,000 when he becomes CEO at closing
Separation of Automotive and Industrial businesses targeted for the first quarter of 2027
Bert Nappier named Executive Vice President, Chief Operating Officer and Chief Financial Officer, effective September 6, 2026; James Howe named Motion President and Chief Operating Officer
GPC and Motion investor days scheduled for December 8, 2026 and December 9, 2026
On September 8, 2026, Centerspace entered a merger agreement under which Independence Realty Trust (IRT) will acquire it in an all-stock transaction, with each Centerspace common share converted into 3.8 IRT common shares. Closing requires Centerspace and IRT shareholder approvals, an effective Form S-4 registration statement, lender consents, and other conditions, and the agreement can be terminated if the merger is not completed by June 30, 2027. For shareholders, the deal would replace their Centerspace shares with IRT shares, so the value they receive will move with IRT's share price.
Exchange ratio of 3.8 IRT common shares for each Centerspace common share, with cash paid in lieu of fractional shares
Termination fees of $45 million payable by Centerspace and $60 million payable by IRT under specified circumstances
Merger can be terminated if not completed by June 30, 2027; presentation says closing could occur as soon as the end of Q4 2026
Until closing, Centerspace may pay regular quarterly dividends of up to $0.77 per share, then a stub dividend of up to $0.09 per share in the closing quarter
Definitive Healthcare disclosed that representatives of its tax receivable agreement (TRA) holders have irrevocably waived the right to an Early Termination Payment tied to any change of control with a definitive merger agreement signed on or before December 31, 2026. The TRA will terminate upon consummation of such a qualifying change of control, while TRA holders keep their other rights, including tax benefit payments for prior and current years.
Waiver covers change-of-control transactions with a definitive merger agreement executed on or before December 31, 2026.
Upon consummation of a qualifying change of control, the TRA terminates under its terms.
TRA holders keep rights to tax benefit payments for taxable years ending before, with, or including the transaction.
The company says it is not a party to the waiver; the filing gives no dollar amounts.
Analog Devices agreed to acquire Alif Semiconductor, a maker of low-power microcontrollers and fusion processors with AI/ML acceleration, in an all-cash deal for $1.35 billion upfront plus up to $200 million in contingent consideration. The filing says the deal is expected to close in the fourth quarter of calendar 2026, subject to closing conditions and Hart-Scott-Rodino antitrust review, and both boards have approved it.
Upfront consideration: $1.35 billion in cash to Alif stockholders
Contingent consideration: up to $200 million additional payment
Expected close: fourth quarter of calendar 2026, subject to Hart-Scott-Rodino waiting period and customary conditions
Advisors: PJT Partners to ADI; Qatalyst Partners to Alif
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.